Heart & Cardiovascular Disease • ICD-10-CM I42.7
Cardiomyopathy due to drug and external agent
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM I42.7 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Marcus Thorne, MD, FACC (NPI #1184629314)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Cardiomyopathy due to drug and external agent Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code I42.7 in Heart & Vascular, Cardiomyopathy due to drug and external agent requires transthoracic echocardiography [Cardiomyopathy due to drug and external agent I42.7] so specialists can calibrate treatment intensity against Left Ventricular Ejection in Cardiomyopathy due to drug and external agent (I42.7: Fraction (LVEF)) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Cardiomyopathy due to drug and external agent uses ICD-10 I42.7 across Heart & Vascular specialty care.
- 3 Typical cash cost range: Clinicians assessing Cardiomyopathy due to drug and external agent focus on structural ventricular wall in Cardiomyopathy due to drug and external agent (I42.7: stress) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Cardiomyopathy due to drug and external agent: maintaining Left Ventricular Ejection in Cardiomyopathy due to drug and external agent (I42.7: Fraction (LVEF)) within 55% – 70% (I42.7).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Cardiomyopathy due to drug and external agent
What Is Cardiomyopathy due to drug and external agent?
Cataloged under federal diagnostic code I42.7 in Heart & Vascular, Cardiomyopathy due to drug and external agent requires transthoracic echocardiography [Cardiomyopathy due to drug and external agent I42.7] so specialists can calibrate treatment intensity against Left Ventricular Ejection in Cardiomyopathy due to drug and external agent (I42.7: Fraction (LVEF)) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Cardiomyopathy due to drug and external agent (I42.7) features structural ventricular wall in Cardiomyopathy due to drug and external agent (I42.7: stress). therapeutic stabilization in heart & vascular is verified against NT-proBNP [Cardiomyopathy due to drug and external agent I42.7].
Common Symptoms & Clinical Signs
- • Presentation of Cardiomyopathy due to drug and external agent (I42.7): shortness of breath in Cardiomyopathy due to drug and external agent (I42.7: when climbing stairs)
- • Secondary Cardiomyopathy due to drug and external agent clinical sign: palpitations, skipped beats, in Cardiomyopathy due to drug and external agent (I42.7: or irregular resting)
- • Symptom flares in Cardiomyopathy due to drug and external agent correlating with Left Ventricular Ejection in Cardiomyopathy due to drug and external agent (I42.7: Fraction (LVEF)) deviation outside 55% – 70% (I42.7)
- • Functional heart & vascular impact requiring transthoracic echocardiography [Cardiomyopathy due to drug and external agent I42.7] evaluation (I42.7)
Cardiomyopathy due to drug and external agent Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I42.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Cardiomyopathy due to drug and external agent (I42.7: Fraction (LVEF)) | 55% – 70% (I42.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Cardiomyopathy due to drug and external agent I42.7] | < 100 pg/mL (I42.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Cardiomyopathy due to drug and external agent I42.7] | < 14 ng/L (I42.7) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Cardiomyopathy due to drug and external agent
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Microvara (Probiotic Dietary Supplement) Microvara • RxCUI RXN-B85477711 | FDA Prescription Therapeutic Agent | 75% | $2.4300 | $ 183.46 /mo |
| Ameluz (Aminolevulinic Acid Hydrochloride) Ameluz • RxCUI RXN-B70621101 | Optical Imaging Agent | 94% | $0.2000 | $ 22.90 /mo |
| E-Z-Paque (Barium Sulfate) E-Z-Paque • RxCUI RXN-B32909750 | Radiographic Contrast Agent | 77% | $1.9300 | $ 147.46 /mo |
| Anticoagulant Citrate Dextrose (Acd) Anticoagulant Citrate Dextrose (Acd) Generic • RxCUI RXN-09429001-3063 | Calculi Dissolution Agent | 93% | $2.0100 | $ 89.91 /mo |
| Omniscan (Gadodiamide) Omniscan • RxCUI RXN-B04070690 | Paramagnetic Contrast Agent | 84% | $1.1800 | $ 93.46 /mo |
| Bystolic (Nebivolol Hydrochloride) Bystolic • RxCUI 387013-B04561405 | beta-Adrenergic Blocker | 88% | $6.1252 | $ 6.25 /mo |
| Icotyde (Icotrokinra) Icotyde • RxCUI 2739042 | FDA Prescription Therapeutic Agent | 77% | $280.0348 | $ 640.00 /mo |
| Nulev (Hyoscyamine Sulfate) Nulev • RxCUI 1046985 | Gastrointestinal Agent | 81% | $0.1442 | $ 9.66 /mo |
| Indocyanine Green Ic-Green, Zyogreen • RxCUI RXN-707102018-1793 | Diagnostic Dye | 89% | $2.3700 | $ 104.49 /mo |
| Ketamine Hydrochloride Ketalar • RxCUI 206967 | General Anesthetic | 91% | $0.6682 | $ 35.56 /mo |
| Mesnex (Mesna) Mesnex • RxCUI RXN-B83703559 | Cytoprotective Agent | 84% | $0.6600 | $ 56.02 /mo |
| Lamictal (Lamotrigine) Lamictal • RxCUI 282401-B01730633 | Anti-epileptic Agent | 80% | $10.2744 | $ 5.59 /mo |
| Elahere (Mirvetuximab Soravtansine) Elahere • RxCUI 2621559 | FDA Prescription Therapeutic Agent | 83% | $3.0500 | $ 228.10 /mo |
| Technetium Tc 99m Medronate Technetium Tc 99m Medronate Generic • RxCUI RXN-65857505-1749 | Radioactive Diagnostic Agent | 82% | $1.0500 | $ 51.03 /mo |
| Gadoterate Meglumine Dotarem, Clariscan • RxCUI RXN-70436123-1767 | Gadolinium-based Contrast Agent | 93% | $0.8000 | $ 40.90 /mo |
| Dilantin Infatabs (Phenytoin) Dilantin Infatabs • RxCUI 1313885-B00710007 | Anti-epileptic Agent | 74% | $1.5696 | $ 121.51 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cardiomyopathy due to drug and external agent)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Causes of heart and blood vessel Hospitalization and Death in Patients With: What a 264-Participant Study Found These data provide further insight into CV disease progression in patients with ATTR-CM, with HF the most common adjudicated cause of CV-related hospitalization or death in ATTR-ACT. The American journal of cardiology • 2021-06-01 • Phase III Randomized Trial | N = 264 | 93/100 | PMID 33667442 ↗ |
| New Insights on Mavacamten - a new disease-specific option for pharmacological treatment of: What a 251-Participant Study Found The safety profile of mavacamten was similar to that of placebo. Kardiologia polska • 2021-01-15 • Phase III Randomized Trial | N = 251 | 93/100 | PMID 34268723 ↗ |
| New Insights on Acoramidis on clinical stability in transthyretin amyloid cardiomyopathy:: What a 611-Participant Study Found Acoramidis led to CMI from baseline in NT-proBNP concentration or 6MWD in a considerable proportion of participants with ATTR-CM. European journal of heart failure • 2026-10-28 • Phase III Randomized Trial | N = 611 | 93/100 | PMID 41771146 ↗ |
| Can This Approach Help? Inside the Latest Research on Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in The baseline characteristics of CARDIO-TTRansform were consistent with previous ATTR-CM trials; however, CARDIO-TTRansform evaluated patients with a wide range of disease severity and receiving the contemporary standard of... European journal of heart failure • 2026-10-28 • Phase III Randomized Trial | N = 130 | 88/100 | PMID 42217207 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term efficacy of tafamidis in patients with transthyretin amyloid Tafamidis treatment reduced the risk of mortality and hospitalization in patients with NAC stages I/II ATTR-CM, with favourable trends at stage III. European journal of heart failure • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40488446 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Cardiomyopathy due to drug and external agent Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Cardiomyopathy due to drug and external agent community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Cardiomyopathy due to drug and external agent.